Inmagene Biopharmaceuticals

Inmagene, with wholly owned subsidiaries in San Diego, Shanghai, Hangzhou and Wuhan, is a leading biotech company focused on immunology-related therapeutic areas. Believing in "borderless innovation", the Inmagene team integrates efficient resources worldwide to develop drugs for global patients. It also in-licenses products for the Asia markets and, together with its partners, carries out global development activities, including multi-regional clinical trials. The company is building a robust pipeline of over 10 drug candidates. Izokibep (IMG-020), Inmagene’s most advanced drug candidate, is about to enter the global phase 2 or 3 trials for multiple indications. Inmagene has a seasoned management team. In prior experience, the team members played important roles in the founding of Zai Lab (NASDAQ: ZLAB), I-Mab (NASDAQ: IMAB) and Apollomics, led the drug development for over 20 successful NDAs, in-licensed over 30 global products for China, obtained market approvals in 28 countries, and pushed 6 drug candidates from discovery to human trials in both China and the United States.